Clinical trials
Lung Fibrosis clinical trials
Below are recruiting lung fibrosis clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03800017Recruiting
Muscle strength and exercise function in lung scarring
This study looks at how well skeletal (muscle) function supports exercise in people with interstitial lung diseases (including idiopathic pulmonary fibrosis). It may help better understand fitness and breathing limits, which can guide rehabilitation choices and future care.
Vancouver, British ColumbiaAges 40–80 - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT07373288Recruiting
HOXB7 and lung markers in pulmonary fibrosis
This study looks at a protein called HOXB7 and other markers in lung tissue and blood to better understand pulmonary fibrosis. It may help researchers find new ways to diagnose or treat the disease.
ModenaAges 18–80 - NCT05895409Recruiting
Study risk factors in progressive lung scarring
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
Jinan, ShandongAges 18–80 - NCT06815185Recruiting
Counseling help for people with interstitial lung disease
This study tests a counseling program to help people with interstitial lung disease (a group of lung conditions that cause scarring and make breathing harder) with rehabilitation and support. It may help you cope better and stay active.
Bologna, BolognaAges 18 years+ - NCT00470327Recruiting
Study of how interstitial lung disease naturally changes
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Chicago, IllinoisAges 18 years+ - NCT06615492Recruiting
Lung transplant study: comparing two ECMO methods
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06339593RecruitingEarly Phase 1
Using MRI to Monitor CF Lung Health
This study uses MRI scans to monitor lung health in teens and young adults with cystic fibrosis who are taking Trikafta. It aims to find better ways to track how the disease affects the lungs over time.
Cincinnati, OhioAges 12–21 - NCT06262282Enrolling by invitation
Phage therapy for stubborn NTM infection in cystic fibrosis
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
Birmingham, AlabamaAges 6 years+ - NCT06032273Recruiting
Lung Transplant Study for CF Patients and Their Caregivers
This study looks at a website-based program to support people with cystic fibrosis (CF) and their caregivers, helping them prepare for a possible lung transplant. It aims to ease stress, provide information, and improve the transplant journey.
Seattle, WashingtonAges 18 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT05937815Recruiting
Study of Trikafta on Gut-Lung Connection in CF
This study is looking at how a new combination medicine (Trikafta) affects the lungs and gut in people with cystic fibrosis who carry the DeltaF508 mutation. It aims to understand how the medicine works in the body.
BordeauxAges 6–17 - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Santa Barbara, CaliforniaAges 18–85 - NCT03120481Recruiting
Check how respiratory health changes in people without lung problems
This trial enrolls adults who recently had a chest X-ray as part of routine health screening and did not show major abnormal findings, and who do not have significant breathing symptoms. It may help researchers understand changes in respiratory health over time and improve how respiratory disease risk is monitored.
Seoul, SeoulAges 19–90 - NCT05727852Enrolling by invitation
Breath and heart tests to study lung disease stiffness
This study uses breath analysis and heart/electrical heart testing to look at how stiff the arteries are in people with long-term lung conditions. It may help researchers better understand lung disease effects on the cardiovascular system.
MoscowAges 18 years+ - NCT04026360Recruiting
Study early lung, virus, and gut changes in children with cystic fibrosis
This study looks at how a child’s early lung function, viral infections, and gut (microbiome) changes affect cystic fibrosis over time. It may help doctors understand what predicts how lung disease develops, which could improve future care.
BernAges birth–18 years - NCT06251687Recruiting
Cryobiopsy for diagnosing progressive pulmonary fibrosis
This trial is testing a new, less invasive way to take a lung tissue sample (called transbronchial cryobiopsy) to help diagnose progressive pulmonary fibrosis (PPF). It may help doctors find the cause of your lung scarring without needing a larger surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT07816185RecruitingPhase 3
Inhaled study drug for pulmonary hypertension with lung scarring
This study tests an inhaled medication called mosliciguat for people with pulmonary hypertension (high blood pressure in the lungs) caused by certain types of lung scarring. It may help improve your ability to exercise and manage symptoms.
Kissimmee, FloridaAges 18–85 - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT03500731RecruitingPhase 1/Phase 2
Lung and bone marrow transplant for lung and blood failure
This Phase 1/2 study tests a special lung-and-bone-marrow transplant approach for people with severe lung disease and bone marrow failure (low blood counts). The goal is to see if the treatment is safe and whether it can improve outcomes when standard long-term immune-suppressing medicines are a poor fit.
Pittsburgh, PennsylvaniaAges 18–60 - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06998043RecruitingPhase 2
Phage therapy for cystic fibrosis with pseudomonas lung infection
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
Birmingham, AlabamaAges 18 years+ - NCT07061873Enrolling by invitation
Exercise program for adults with lung disease
This study tests a physical exercise program designed for adults with diffuse interstitial lung disease. It aims to help improve your breathing and daily function through supervised exercise in a pulmonary rehabilitation setting.
Temuco, CautínAges 18 years+ - NCT00943514Recruiting
Study of bronchiectasis and why infections keep coming back
This study follows children (age 5+) and adults with bronchiectasis or ongoing/repeated lung infections to learn what makes infections more likely. It mainly looks at non–cystic fibrosis causes, but may include some related conditions to compare differences.
Bethesda, MarylandAges 5–100
Hear when a new Lung Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung fibrosis?
- Yes. Clin2 currently lists 80 recruiting lung fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.